echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > ARD: Short-, medium-, and long-term risk of acute coronary syndrome in a cohort of RA patients using biological DMARDs: results from four Nordic countries

    ARD: Short-, medium-, and long-term risk of acute coronary syndrome in a cohort of RA patients using biological DMARDs: results from four Nordic countries

    • Last Update: 2022-04-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Objective: Patients with rheumatoid arthritis (RA) are at increased risk of acute coronary syndrome (ACS) and other cardiovascular diseases, but different biological / targeted synthetic disease-modifying antirheumatic drugs (b/ tsDMARDs) is unclear, and most studies compared the risk of one b/tsDMARD to another, not all available b/ tsDMARDs
    .


    The aim of this study was to compare the 1- , 2- , and 5 -year ACS incidence in patients with RA who were initiated on any of the biological disease-modifying antirheumatic drugs (bDMARDs) currently available in clinical practice, and with the general population .

    Objective: Patients with rheumatoid arthritis (RA) are at increased risk of acute coronary syndrome (ACS) and other cardiovascular diseases, but different biological / targeted synthetic disease-modifying antirheumatic drugs (b/ tsDMARDs) is unclear, and most studies compared the risk of one b/tsDMARD to another, not all available b/ tsDMARDs


    Methods: Observational cohort study of patients from Denmark, Finland, Norway, and Sweden who started bDMARD therapy between 2008 and 2017 .


    Determine the time of your first ACS via the registration link .


    Methods: Observational cohort study of patients from Denmark, Finland, Norway, and Sweden who started bDMARD therapy between 2008 and 2017 .
    Determine the time of your first ACS via the registration link .
    We calculated 1- , 2- , and 5 -year incidence rates (IR) (after drug therapy and treatment initiation) and compared ACS incidence across treatments (taking into account ACS risk factors) using Cox regressions (HRs ) .
    Further separate analyses were performed in subgroups defined by age, number of previous bDMARDs , and history of cardiovascular disease .
    The investigators also compared ACS incidence with a separately matched general population cohort .

    RESULTS: A total of 24,083 patients ( 75% women, mean age 56 years) of 40,850 courses were included .


    During the longest ( 5 -year) follow-up period ( 141,257 person-years ( pyrs )), 780 ACS events occurred (crude IR 5.
    5/1000 pyrs ) .
    Overall, the incidence of ACS in RA is 80% higher than in the general population .
    HR was close to 1 (etanercept as reference) for all bDMARDs and different follow-up time points, except for the 5 -year risk window, where abatacept ( ABA ), infliximab ( INF ) and rituximab ( RIT ) HR value greater than 1 .

    RESULTS: A total of 24,083 patients ( 75% women, mean age 56 years) of 40,850 courses were included .
    During the longest ( 5 -year) follow-up period ( 141,257 person-years ( pyrs )), 780 ACS events occurred (crude IR 5.
    5/1000 pyrs ) .
    Overall, the incidence of ACS in RA is 80% higher than in the general population .
    HR was close to 1 (etanercept as reference) for all bDMARDs and different follow-up time points, except for the 5 -year risk window, where abatacept ( ABA ), infliximab ( INF ) and rituximab ( RIT ) HR value greater than 1 .

         Conclusions: Compared with the general population, RA patients using bDMARDs had a higher incidence of ACS .


    The short-, mid-, and long-term risks of ACS did not differ significantly between bDMARDs when used in usual care .
     

         Conclusions: Compared with the general population, RA patients using bDMARDs had a higher incidence of ACS .
    The short-, mid-, and long-term risks of ACS did not differ significantly between bDMARDs when used in usual care .
     

    Source: Delcoigne B, Ljung L, Provan SA , et al .


    Short-term, intermediate-term and long-term risks of acute coronary syndrome in cohorts of patients with RA starting biologic DMARDs: results from four Nordic countries.
    Annals of the Rheumatic Diseases.
      Published Online First: 22 March 2022.
    doi: 10.


    Delcoigne B, Ljung L, Provan SA , et al .
    Short-term, intermediate-term and long-term risks of acute coronary syndrome in cohorts of patients with RA starting biologic DMARDs: results from four Nordic countries.
    Annals of the Rheumatic Diseases.
      Published Online First: 22 March 2022.
    doi: 10.
    1136/annrheumdis-2021-221996 , et al Annals of the Rheumatic Diseases.
      Leave a comment here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.